

PRESS RELEASE

Giovanni Magnaghi is the new Chief Executive Officer of Zambon SpA

Bresso, Italy, May 2nd 2024 - Today, the Board of Directors of Zambon SpA appointed Giovanni Magnaghi as Chief Executive Officer to lead the company in the execution of its strategic plan, based on the strengthening of Zambon's global brands and the development of new therapeutic solutions in the area of severe respiratory diseases - BOS (Bronchiolitis Obliterans Syndrome), NCFB (Non-Cystic Fibrosis Bronchiectasis) - and in the CNS (Central Nervous System) area.

Giovanni Magnaghi, who joined Zambon in 2018 as Group Chief Financial Officer, has created the conditions to achieve successful milestones not only in the finance area, but also through his decisive role in establishing and developing Zambon Biotech, focused on building a scientifically robust and commercially viable medium to long-term portfolio of innovative medicines.

Previously, he worked at Gilead Sciences where, in addition to his role as VP Finance EMEA, he was General Manager giving his contribution to the launch and negotiation of several high-profile drugs globally. His experience also includes positions at Gillette Group, Bausch & Lomb, Henry Schein.

Elena Zambon, president of Zambon Spa, commented: *"Giovanni Magnaghi, thanks to his skills and leadership, together with the entire Executive Management Committee, will be able to define and execute launches in the near future both in the Countries where we already operate and in the US, as well as accelerate the consolidation and growth of our proprietary brands."*

"I am very pleased with the Board's decision - said Giovanni Magnaghi - and well aware of the responsibility involved in being at the helm of a company that, with its 118 years of history, has further growth ahead of it."

The Board of Directors expressed its gratitude to Ilaria Villa, who in her years leading Zambon Spa has strengthened the transformation journey with a constant focus on values.

Zambon SpA

Zambon Spa is a multinational pharmaceutical company established in 1906 in Vicenza, whose history is founded on the values of an Italian family committed to innovating cure & care to improve patients' lives. It employs more than 2,500 people worldwide, is present in 23 countries in Europe, America and Asia, and has production facilities in Italy, Switzerland, China and Brazil. Thanks to its innovative, quality products commercialized in 87 countries, Zambon Spa reported a revenue of 843 million euros in 2023. Alongside the three historical therapeutic areas - diseases of the respiratory system, urinary tract infections and pain treatment – Zambon is focused on developing treatments for neurodegenerative diseases such as Parkinson's or rare diseases such as cystic fibrosis, BOS, to which is linked the major 2019 acquisition of Breath Therapeutics, and NCFB. For further information on Zambon please visit www.zambon.com

Media Contacts: media@zambongroup.com

Francesco Guidara +39 349 75.82.952, francesco.guidara@zambongroup.com

Marco Allegrini +39 347 33.95.615, marco.allegrini@zambongroup.com